(2S,4R)-1-(Tert-Butoxycarbonyl)-4-Hydroxypyrrolidine-2-Carboxylic Acid

In solid-phase peptide synthesis (SPPS) employing a Boc/Benzyl protection strategy, introduction of the trans-4-hydroxy-L-proline residue requires a building block that withstands repetitive TFA-mediated N^α-deprotection without premature side-chain acylation. (2S,4R)-1-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid, stored under anhydrous conditions at 2–8 °C with a headspace purged of atmospheric moisture, is dissolved in N-methylpyrrolidone (NMP) and coupled via its free carboxylic acid using 4.0 molar equivalents of the amino acid with respect to free amine-loading on aminomethylated polystyrene resin, activated by HBTU (3.9 equiv.) in the presence of 0.4 M N-methylmorpholine. The coupling reaction, allowed to proceed for 45–60 minutes at 22±3 °C with overhead agitation in a glass solid-phase reactor fitted with fritted disc, is monitored by Kaiser test (ninhydrin reaction) to confirm resin-bound amine consumption; a negative test indicates ≥99.5% coupling efficiency. Post-coupling, the N-terminal Boc group is removed with 50% (v/v) trifluoroacetic acid in dichloromethane containing 2% triisopropylsilane as carbocation scavenger, with a cleavage time not exceeding 30 minutes to minimize diketopiperazine formation when the downstream residue is proline or sarcosine. Commercial GMP manufacturing of hydroxyproline-containing peptides—such as the fragment Ac-Arg-Gly-Hyp-Ser-Gly-OH intended for collagen mimetic peptide APIs—follows ICH Q7 §12 requirements for peptide coupling agents, while residual solvent limits for dichloromethane (600 ppm), N,N-dimethylformamide (880 ppm), and trifluoroacetic acid (0.1% in the final peptide) are set in alignment with ICH Q3C Option 1 for Class 2 solvents and Ph.Eur. 5.4 monograph on residual solvents. The final peptide, purified by preparative RP-HPLC on a C18 column with a mobile phase of 0.1% TFA in water/acetonitrile, is isolated as an acetate salt by ion exchange, lyophilized, and released according to USP Chapter <621> for chromatographic identity and USP <1205> for endotoxin, enabling its incorporation into injectable collagen-stimulating therapeutics that rely on triple-helical nucleation motifs.

Can (2S,4R)-1-Boc-4-Hydroxyproline Suppress Epimerization at the Pyrrolidine C‑4 Stereocenter During the Multi‑Step Bicyclic Proline Assembly for 3CL Protease Blockers?

Synthesis of the (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid warhead—shared by the SARS-CoV-2 3CL protease inhibitor nirmatrelvir (Paxlovid) and the hepatitis C virus NS3/4A protease inhibitor boceprevir—initiates from (2S,4R)-1-Boc-4-hydroxyproline at a fixed 1.00 molar equivalent stoichiometric loading, wherein the C‑4 hydroxyl stereochemical integrity directly governs endo/exo diastereoselectivity of the subsequent cyclopropane ring closure. In a jacketed 500‑L glass-lined reactor equipped with retreat-curve impeller and controlled at −12 °C ± 2 °C, the secondary alcohol is oxidized to 4-ketoproline using an aqueous NaOCl/TEMPO biphasic system buffered to pH 8.5–9.0, with continuous ORP monitoring; hypochlorite dosage is ramped over 90 minutes at a rate that maintains molar excess below 5% over the substrate to avoid oxidative decarboxylation, and the keto intermediate is extracted into methyl tert‑butyl ether, dried over molecular sieves 4A, and concentrated to a moisture content below 0.05% before the Wittig olefination. The addition of methyltriphenylphosphonium bromide (1.3 equiv.) pre-mixed with potassium tert‑butoxide (1.25 equiv.) in anhydrous THF at 0–5 °C generates the exocyclic olefin in 92–94% crude yield; subsequent in situ Corey–Chaykovsky cyclopropanation using trimethylsulfoxonium iodide (1.5 equiv.) and NaH (1.45 equiv.) in DMSO at 18–22 °C yields the bicyclic proline skeleton with a diastereomeric ratio (dr) typically ranging from 96:4 to 98:2 favoring the (1R,2S,5S) isomer, as quantitated by chiral HPLC (Chiralpak AD‑H column, heptane/ethanol 85:15 with 0.1% TFA) per Ph.Eur. 2.2.46 guidelines. Process characterization studies have placed emphasis on the criticality of the oxidation step, where temperature excursions above −8 °C induce epimerization at C‑2 (α‑carbon) through Schiff base formation with TEMPO-generated iminium intermediates, increasing the (2R)‑enantiomeric impurity above the 0.15% reporting threshold specified in ICH Q11 for starting materials intended for an API with a chiral center count of four. Pharmaceutical-grade regulations for this starting material are enforced through ICH Q7 §7.1 quality unit oversight, with specifications mandating chiral purity by HPLC (Ph.Eur. 2.2.64), residual palladium below 10 ppm (if hydrogenolysis is applied upstream to remove a benzyl ester), and total aerobic microbial count <100 CFU/g with absence of Escherichia coli per USP <61>/<62>. The terminal drug substances nirmatrelvir and boceprevir, crystallized from acetonitrile/water with seed‑bed control, are formulated as film‑coated tablets co‑administered with ritonavir for pharmacokinetic boosting or, respectively, as part of a direct‑acting antiviral regimen for genotype 1 HCV infection.

Vildagliptin Route Scouting: Defining the Enantiopurity Trajectory from Hydroxyproline to (S)‑Pyrrolidine‑2‑carbonitrile under Anhydrous Vilsmeier Conditions

A process route to the dipeptidyl peptidase‑4 inhibitor vildagliptin that avoids chromatographic chiral separation relies on (2S,4R)-1-Boc-4-hydroxyproline as the chiral pool origin for the pyrrolidine‑2‑carbonitrile pharmacophore, requiring the removal of the C‑4 hydroxyl group while simultaneously converting the carboxylic acid to a nitrile. The raw material is charged at 1.0 kg scale per batch into a 20 L Hastelloy C‑22 reactor and esterified with methanol‑thionyl chloride (1.2 equiv., −5 to 0 °C) to generate the methyl ester hydrochloride, followed by liberation of the free amine with methanolic ammonia and reprotection with Boc anhydride to restore the carbamate. The hydroxyl group is activated in a subsequent step through mesylation (methanesulfonyl chloride, 1.1 equiv., triethylamine 1.3 equiv. in dichloromethane at 0 °C), and elimination is promoted by DBU (2.0 equiv.) in refluxing toluene, providing the 3,4-dehydroproline derivative with an E/Z ratio that is inconsequential for downstream hydrogenation. Continuous‑flow hydrogenation over Raney nickel (slurry at 0.5 wt% substrate concentration, H₂ pressure 3.5 bar, residence time 12 min) saturates the double bond and preserves the C‑2 (S) stereochemistry with chiral HPLC confirming <0.3% of the (R)-enantiomer, measured against a certified reference standard traceable to Ph.Eur. monograph 3107 for l‑proline. The ester is saponified with LiOH (1.05 equiv.) in THF/water to the free acid, which is then subjected to an amidation‑dehydration sequence: activation with ethyl chloroformate (1.1 equiv.) and N‑methylmorpholine in THF at −20 °C forms the mixed anhydride, quenched with aqueous ammonia (30% w/w) to give the primary amide, and POCl₃ (1.0 equiv.) in DMF‑pyridine at 0–5 °C dehydrates the amide to the nitrile. Critical quality attributes for the intermediate crystallized Boc‑pyrrolidine‑2‑carbonitrile include melting point range 68–71 °C, water content <0.3% by Karl Fischer (USP <921>), and any single unknown impurity ≤0.10%. The industry‑accepted specification sheet references ICH Q3D for elemental impurities with specific scrutiny of nickel (limit 20 µg/g) and palladium, and the overall synthesis aligns with ICH Q11 essential guidance for a starting material that is no more than three synthetic steps removed from the API. The final active pharmaceutical ingredient, vildagliptin, is co‑formulated with metformin in a fixed‑dose combination tablet and is indicated for glycemic control in type‑2 diabetes mellitus.

Asymmetric Transfer Hydrogenation Ligand Architecture: The Economic Case for Hydroxyproline‑Backboned Amino Alcohols in Industrial Ruthenium Catalysis

When a bench‑stable N‑sulfonylated diamine ligand derived from proline fails to provide the required enantiomeric excess (ee) for acetophenone reduction under phase‑transfer conditions, a hydroxyproline‑backboned β‑amino alcohol scaffold, synthesized from (2S,4R)-1-Boc-4-hydroxyproline, furnishes a ligand that coordinates to [RuCl₂(p‑cymene)]₂ in isopropanol with an induction typically above 97% ee for prochiral aromatic ketones. The synthetic sequence entails the reduction of the carboxylic acid moiety to hydroxymethyl using a BH₃·THF complex (2.5 equiv.) in THF at 0–25 °C, yielding the corresponding β‑amino alcohol after an aqueous quench with NaOH; the tri‑stage work‑up, including treatment with ion‑exchange resin Amberlyst 15 to cleave the borate ester, is validated by ¹¹B NMR to confirm residual boron levels <5 ppm. The Boc‑protected hydroxyprolinol is subsequently tosylated at the primary alcohol, displaced by aniline (1.8 equiv.) in acetonitrile at reflux, and then deprotected with TFA to deliver the N‑monoalkylated diamine. The ligand is converted to its ruthenium complex by refluxing with [RuCl₂(p‑cymene)]₂ (0.5 equiv.) and triethylamine in isopropanol at 80 °C for 2 h in a Schlenk flask under argon, and used in situ for the asymmetric transfer hydrogenation of acetophenone with a substrate‑to‑catalyst (S/C) ratio of 500:1 and formic acid‑triethylamine azeotrope (5:2 molar ratio) as the hydride source. Recycling experiments on a 50‑L pilot‑plant scale achieve catalyst turnover numbers exceeding 1000 with no detectable ruthenium leaching into the organic phase, as confirmed by ICP‑MS analysis (LOQ 0.01 µg/L), which aligns with the ICH Q3D permitted daily exposure for oral elemental impurities. The regulatory framework for the chiral ligand market is primarily governed by REACH (EC) No 1907/2006 Title II for registration of substances manufactured ≥1 tonne per annum within the European Economic Area, and the generated (R)‑alcohol products—such as (R)‑3,5‑bis(trifluoromethyl)‑α‑methylbenzyl alcohol—are utilized as key chiral synthons in the preparation of neurokinin‑1 receptor antagonists and other respiratory or chemotherapy‑induced nausea inhibitors.

The cosmetic peptide sector’s demand for chirally pure building blocks has driven large‑scale procurement of (2S,4R)-1-Boc-4-hydroxyproline for the synthesis of palmitoyl hydroxyproline, a skin‑identical lipoamino acid that strengthens the dermal extracellular matrix through stimulation of collagen fragment condensation. In a two‑phase reaction system consisting of ethyl acetate and an aqueous sodium bicarbonate buffer maintaining pH 9.0–9.5, the Boc‑protected acid is reacted with palmitoyl chloride (1.02 molar equivalents) under vigorous agitation in an in‑line rotor‑stator homogenizer operated at 3000 rpm; the exothermic chloro‑amide formation is controlled by jacket cooling at 8±2 °C, and the reaction endpoint is determined by TLC (silica, chloroform‑methanol 9:1) not by visual clarification, due to emulsion persistence. After phase separation and washing with 0.5 M citric acid and brine, the Boc intermediate is concentrated and subjected to neat TFA at 20–25 °C for 45 min, quenched into ice‑water, and pH‑adjusted to 6.0 with ammonium hydroxide to precipitate the free amine as a white filterable powder. Quality control of the final “Palmitoyl Hydroxyproline” (INCI name) for topical leave‑on formulations includes peroxide value by USP <401> (limit <5.0 meq/kg), acid value 125–145 mg KOH/g by ISO 660:2020, saponification value 140–160 mg KOH/g by ISO 3657:2020, microbiological enumeration meeting EU Cosmetic Regulation 1223/2009 Annex I limits (TAMC <100 CFU/g, TYMC <10 CFU/g), and absence of nitrosating agents as per COSMOS-standard Annex 4. The ingredient is incorporated at 0.5–2.0 wt% into anti‑aging serums, where it serves as a lipophilic derivative that partitions into the stratum corneum lipid bilayers, and is further formulated alongside hyaluronic acid and acetyl dipeptide‑1 cetyl ester to produce cosmetic finished goods making “pro‑collagen” claims substantiated by in‑vitro fibroblast elastase inhibition assays.

Antibody‑drug conjugate (ADC) linker‑payload development frequently requires a functionalizable proline derivative that can space the cytotoxic payload from the cleavable dipeptide sequence while also providing a bioorthogonal click‑chemistry anchor. (2S,4R)-1-Boc-4-hydroxyproline is quantitatively converted to (2S,4S)-1-Boc-4-azidoproline through a Mitsunobu‑type inversion using diphenyl phosphoryl azide (DPPA, 1.2 equiv.) and diisopropyl azodicarboxylate (1.2 equiv.) with triphenylphosphine (1.3 equiv.) in dry THF at −10 to 0 °C; the exotherm is managed by slow addition of DIAD over 40 min, and the (2S,4S)-azide stereochemistry is confirmed by ¹H NMR coupling constant J_3,4 ≈ 5.2 Hz. The azide‑appended pyrrolidine is then deprotected and used in copper‑catalyzed azide‑alkyne cycloaddition (CuAAC) with a strained cyclooctyne–PEG₈‑maleimide heterobifunctional linker to create a homogeneous DAR‑4 conjugate precursor. During pilot‑scale batches of the azido intermediate produced under cGMP conditions (compliant with ICH Q7 §12 for specialty chemical manufacturing that supports IND‑enabling activities), residual hydrazoic acid generated from DPPA is quenched in‑process with sodium nitrite (1.0 M) and monitored by ion chromatography to ensure headspace concentration below the OSHA TWA of 0.1 ppm. The azido‑pyrrolidine product, after flash chromatography on silica gel (ethyl acetate‑hexane 1:4) and drying under reduced pressure at 30 °C for 16 h, must comply with residual solvent specifications of ethyl acetate <5000 ppm, THF <720 ppm, and triphenylphosphine oxide <0.1% by HPLC, as the oxide interferes with downstream protein conjugation efficiency. Terminal ADC candidates incorporating such hydroxyproline‑derived linker technology include next‑generation Trop‑2‑targeting immunoconjugates (e.g., sacituzumab govitecan analogs) and STING agonist ADCs, wherein the rigid pyrrolidine spacer influences bystander killing effect and lysosomal processing kinetics, all monitored in‑vitro by capillary isoelectric focusing per USP <1053> to determine average drug‑to‑antibody ratio.

Process engineering for kilogram‑scale production of the (1R,2S,5S)-bicyclic ester destined for boceprevir often involves a telescoped sequence where the crude olefin solution from the Wittig step is filtered through a pad of Celite‑545 to remove triphenylphosphine oxide, concentrated below 40 °C under 200 mbar, and directly subjected to the Corey–Chaykovsky reagent; published data for this specific telescoped configuration is limited, but internal technical reports indicate that an in‑line FTIR probe monitoring the P=O stretch at 1190 cm⁻¹ provides a real‑time release criterion for the olefin quality, reducing the cycle time by eight hours compared to a fully isolated intermediate approach and simultaneously suppressing the formation of the (1S,2R,5R) stereoisomer to below the 0.10% detection threshold when the trimethylsulfoxonium iodide addition is staged over three equal portions at 45‑min intervals. During the transfer of this process to a multi‑product contract manufacturing facility, a critical equipment‑specific failure mode was identified: the Hastelloy C‑276 agitator shaft in the oxidation reactor exhibited pitting corrosion after 12 batches when the aqueous NaOCl phase contact exceeded 100 minutes per batch, necessitating a switch to a glass‑lined vessel with tantalum thermocouple sheath and a reduction of the organic phase residence time at the neutralization step through a continuous mixer‑settler arrangement. The bis‑hydrochloride salt of the bicyclic amino acid is isolated from acetonitrile/water recrystallization and utilized in the final peptide coupling with the cyclopropyl aminobutyramide moiety, with a yield over the seven‑step sequence from (2S,4R)-1-Boc-4-hydroxyproline typically achieving 42–48% and a purity profile sufficient to satisfy USP monographs for direct‑acting antivirals, including the enantiomeric purity clause that the sum of all epimers does not exceed 1.0% as an acceptance criterion in the drug substance specification.